SEC Form 4 · accession 0000769993-15-000792
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 19, 2015
Accepted (ET)
Jun 29, 2015 · 12:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $18.59 | Jun 19, 2015 | A | 17,647 | A | — | — | Common Stock | 17,647 | 17,647 | I |
Explanation of responses
- F1This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman, Sachs & Co. ("Goldman Sachs," and together with GS Group, the "Reporting Persons"). Goldman Sachs is a wholly-owned subsidiary of GS Group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
- F2The options to purchase 17,647 shares of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. (the "Company") were granted to Thomas J. Carella, a managing director of Goldman Sachs, in his capacity as a director of the Company pursuant to the T2 Biosystems, Inc. Non-Employee Director Compensation Program under the T2 Biosystems, Inc. 2014 Incentive Award Plan. The grant of 17,647 options will vest and become exercisable in twelve substantially equal monthly installments following the grant date, subject to continued board service through each such date. Mr. Carella has an understanding with GS Group pursuant to which such options are held for the benefit of GS Group.